Latest & greatest articles for tiotropium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tiotropium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tiotropium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tiotropium

41. Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis

Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis Wang J, Jin D, Zuo P, Wang T, Xu Y, Xiong W CRD summary This review found that tiotropium plus formoterol significantly (...) improved lung function and symptom scores compared with tiotropium alone in patients with stable chronic obstructive pulmonary disease. The authors recommended further research to establish long-term efficacy and safety of the combination. The conclusions reflect the evidence presented and are likely to be reliable. Authors' objectives To compare the efficacy and safety of tiotropium plus formoterol with that of tiotropium alone in patients with stable chronic obstructive pulmonary disease (COPD

DARE.2011

42. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials

Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis (...) of randomised controlled trials Singh S, Loke YK, Enright PL, Furberg CD CRD summary The authors concluded that there was a 52% increased risk of mortality associated with the tiotropium mist inhaler in patients with chronic obstructive pulmonary disease . This was a well-conducted review and the conclusion is likely to be reliable. Authors' objectives To evaluate the risk of mortality following long-term use of tiotropium delivered using a mist inhaler in patients with chronic obstructive pulmonary disease

DARE.2011

43. Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes

Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes Yohannes AM, Willgoss TG, Vestbo J CRD summary The review found that, compared with placebo or ipratropium, tiotropium improved the quality of life, eased difficulties with breathing, and reduced exacerbations and related (...) hospitalisations in patients with stable chronic obstructive pulmonary disease. The authors' conclusions reflect the evidence base, but because of potential publication and language bias, the conclusions should be considered tentative. Authors' objectives To assess the effectiveness of tiotropium versus placebo, ipratropium and long-acting beta-2 agonists on clinically relevant outcomes in patients with chronic obstructive pulmonary disease (COPD). Searching MEDLINE, EMBASE, CINAHL, AMED, Web of Knowledge

DARE.2011

44. Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD

Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD Sun SX, Marynchenko M, Banerjee R, Cheng D, Mocarski M, Yin D, Yu AP, Wu EQ Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of roflumilast with tiotropium versus tiotropium alone for the management of patients with severe-to-very severe chronic obstructive pulmonary disease (COPD), from the

NHS Economic Evaluation Database.2011

45. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

Tiotropium versus salmeterol for the prevention of exacerbations of COPD. 21428765 2011 03 24 2011 04 04 2015 11 19 1533-4406 364 12 2011 Mar 24 The New England journal of medicine N. Engl. J. Med. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. 1093-1103 10.1056/NEJMoa1008378 Treatment guidelines recommend the use of inhaled long-acting bronchodilators to alleviate symptoms and reduce the risk of exacerbations in patients with moderate-to-very-severe (...) chronic obstructive pulmonary disease (COPD) but do not specify whether a long-acting anticholinergic drug or a β(2)-agonist is the preferred agent. We investigated whether the anticholinergic drug tiotropium is superior to the β(2)-agonist salmeterol in preventing exacerbations of COPD. In a 1-year, randomized, double-blind, double-dummy, parallel-group trial, we compared the effect of treatment with 18 μg of tiotropium once daily with that of 50 μg of salmeterol twice daily on the incidence of moderate or severe exacerbations

NEJM2011

46. Tiotropium Bromide as an Adjunct Therapy to Inhaled Corticosteroids in the Treatment of Adults With Chronic Asthma

Tiotropium Bromide as an Adjunct Therapy to Inhaled Corticosteroids in the Treatment of Adults With Chronic Asthma "Tiotropium Bromide as an Adjunct Therapy to Inhaled Corticosteroids in" by Kevin M. Dennis < > > > > > Title Author Date of Award Winter 3-18-2011 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Asthma is a chronic respiratory disease effecting 24.6 million children and adults in the United States. Current (...) treatment guidelines recommend the use of inhaled corticosteroids and both short and long acting beta agonists. Several systematic reviews have evaluated the use of anticholinergics with mixed results. Tiotropium bromide became available in the United States in 2004, yet there have been few studies utilizing this long acting anticholinergic for the treatment of asthma patients. Purpose: This paper evaluates the current literature on the improvements in pulmonary function in asthmatics with the use

Pacific University EBM Capstone Project2011

47. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.

Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. BACKGROUND: Combination therapy (inhaled corticosteroids and long-acting beta(2)-agonists) and tiotropium are both used in the treatment of chronic obstructive pulmonary disease (COPD). There is uncertainty about the relative benefits and harms of these treatments. OBJECTIVES: To assess the relative effects of inhaled combination therapy and tiotropium on patients with COPD (...) . SEARCH STRATEGY: We searched the Cochrane Airways Group Specialised Register of trials (March 2010) and reference lists of articles. We also contacted authors of the studies. SELECTION CRITERIA: We included only parallel, randomised controlled trials comparing inhaled combination corticosteroid and long-acting beta(2)-agonist against inhaled tiotropium bromide. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trials for inclusion and then extracted data on trial quality and outcome

Cochrane2010

48. Cardiovascular safety of tiotropium in patients with COPD

Cardiovascular safety of tiotropium in patients with COPD 19592475 2010 01 06 2010 02 02 2015 11 19 1931-3543 137 1 2010 Jan Chest Chest Cardiovascular safety of tiotropium in patients with COPD. 20-30 10.1378/chest.09-0011 The clinical trial safety database for tiotropium has been augmented with a 4-year trial in patients with COPD, which provides an opportunity to better evaluate the cardiovascular (CV) profile of tiotropium. Trials with the following criteria were considered: > or = 4 weeks (...) , randomized, double-blind, parallel-group, placebo-controlled. Inclusion/exclusion criteria were similar, including spirometry-confirmed COPD, > or = 10 pack-year smoking, and age > or = 40 years. Adverse events were collected throughout each trial using standardized case report forms. Incidence rates (IRs) were determined from the total number of patients with an event divided by total time at risk. Rate ratios (RRs) and 95% CI for tiotropium/placebo were calculated. IRs were determined for all-cause

EvidenceUpdates2010

49. Effect of tiotropium on quality of life in COPD: a systematic review

Effect of tiotropium on quality of life in COPD: a systematic review Effect of tiotropium on quality of life in COPD: a systematic review Effect of tiotropium on quality of life in COPD: a systematic review Kaplan A CRD summary The author concluded that tiotropium improved the quality of life for patients with chronic obstructive pulmonary disease who required long-acting bronchodilator treatment. Given the unclear quality of included trials, the small number of trials and the absence (...) of clinically significant differences for many trials, the author's conclusions should be treated with caution. Authors' objectives To assess the impact of long-acting anticholinergic tiotropium on health related quality of life in patients with chronic obstructive pulmonary disease (COPD). Searching PubMed, EMBASE and BIOSIS Previews were searched for articles published in English from 1990 to 2009. Search terms were reported. Study selection Double-blind randomised controlled trials (RCTs) that compared

DARE.2010

50. Does tiotropium lower exacerbation and hospitalization frequency in COPD patients? Results of a meta-analysis

Does tiotropium lower exacerbation and hospitalization frequency in COPD patients? Results of a meta-analysis Does tiotropium lower exacerbation and hospitalization frequency in COPD patients? Results of a meta-analysis Does tiotropium lower exacerbation and hospitalization frequency in COPD patients? Results of a meta-analysis Van den Bruel A, Gailly J, Neyt M CRD summary The authors concluded that tiotropium reduced the number of exacerbations and hospitalisations (...) of chronic obstructive pulmonary disease (COPD) patients compared with placebo and ipratropium; compared with salmeterol, only the exacerbation frequency was reduced. Given the variability across trials, the possibility of inappropriate pooling and the poor quality of the evidence base, the authors’ conclusions should be interpreted with caution. Authors' objectives To estimate the effect of tiotropium (a long-acting anticholinergic inhalant) on exacerbation and chronic obstructive pulmonary disease (COPD)-related hospitalisation

DARE.2010

51. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD

Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD Gani R, Griffin J, Kelly S, Rutten-van Molken M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared the cost-effectiveness of tiotropium, ipratropium, and salmeterol, for the treatment of chronic obstructive pulmonary disease. The authors concluded that tiotropium was a cost-effective alternative to ipratropium and salmeterol, and switching patients from ipratropium and salmeterol to tiotropium led to considerable cost savings

NHS Economic Evaluation Database.2010

52. Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease

Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease Naik S, Kamal KM, Keys PA, Mattei TJ Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of tiotropium versus salmeterol for the treatment of patients with moderate chronic obstructive pulmonary disease. The authors concluded that, from the perspective of the third-party payer, tiotropium was more cost-effective than

NHS Economic Evaluation Database.2010

53. Tiotropium bromide step-up therapy for adults with uncontrolled asthma.

Tiotropium bromide step-up therapy for adults with uncontrolled asthma. 20979471 2010 10 28 2010 11 05 2016 12 15 1533-4406 363 18 2010 Oct 28 The New England journal of medicine N. Engl. J. Med. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. 1715-26 10.1056/NEJMoa1008770 Long-acting beta-agonist (LABA) therapy improves symptoms in patients whose asthma is poorly controlled by an inhaled glucocorticoid alone. Alternative treatments for adults with uncontrolled asthma (...) are needed. In a three-way, double-blind, triple-dummy crossover trial involving 210 patients with asthma, we evaluated the addition of tiotropium bromide (a long-acting anticholinergic agent approved for the treatment of chronic obstructive pulmonary disease but not asthma) to an inhaled glucocorticoid, as compared with a doubling of the dose of the inhaled glucocorticoid (primary superiority comparison) or the addition of the LABA salmeterol (secondary noninferiority comparison). The use of tiotropium

NEJM2010 Full Text: Link to full Text with Trip Pro

54. Tiotropium

Tiotropium Tiotropium Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Tiotropium From: Published: 10 November 2010 Therapeutic area: Safety studies of Spiriva Respimat▼ This article has been superseded. See for latest advice Article date: November 2010 Tiotropium is a long-acting muscarinic receptor antagonist that is licensed as a prescription-only medicine for maintenance bronchodilator treatment to relieve symptoms of chronic obstructive pulmonary disease (...) (COPD). Two formulations are available as the brand name Spiriva: a capsule containing 18 micrograms tiotropium delivered via a HandiHaler taken once daily and a soft-mist Respimat inhaler that delivers 2∙5 micrograms tiotropium per actuation taken as two puffs once a day at the same time of the day. Recent safety analyses for Spiriva Respimat▼ MHRA has of a number of recent studies on the safety of inhaled anticholinergic drugs. Although some published studies have suggested an increased risk

MHRA Drug Safety Update2010

55. Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness

Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness Pohar R, Nkansah E Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pohar R, Nkansah E. Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2009 Authors' conclusions In two RCTs, patients with moderate to severe COPD who were

Health Technology Assessment (HTA) Database.2009

56. Tiotropium for moderate-to-severe chronic obstructive pulmonary disease: a review of the clinical effectiveness and cost-effectiveness

Tiotropium for moderate-to-severe chronic obstructive pulmonary disease: a review of the clinical effectiveness and cost-effectiveness Tiotropium for moderate-to-severe chronic obstructive pulmonary disease: a review of the clinical effectiveness and cost-effectiveness Tiotropium for moderate-to-severe chronic obstructive pulmonary disease: a review of the clinical effectiveness and cost-effectiveness Tran K, Nkansah E Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Tran K, Nkansah E. Tiotropium for moderate-to-severe chronic obstructive pulmonary disease: a review of the clinical effectiveness and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2009 Authors' conclusions Compared with LABAs (formoterol, salmeterol), tiotropium was associated with greater improvement of lung function

Health Technology Assessment (HTA) Database.2009

57. Tiotropium in the treatment of chronic obstructive pulmonary disease health technology assessment

Tiotropium in the treatment of chronic obstructive pulmonary disease health technology assessment Tiotropium in the treatment of chronic obstructive pulmonary disease health technology assessment Tiotropium in the treatment of chronic obstructive pulmonary disease health technology assessment Neyt M, Van den Bruel A, Gailly J, Thiry N, Devriese S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Neyt M, Van den Bruel A, Gailly J, Thiry N, Devriese S. Tiotropium in the treatment of chronic obstructive pulmonary disease health technology assessment. Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports 108C. 2009 Authors' conclusions Long-acting bronchodilators are recommended in patients who remain symptomatic despite adequate treatment with short-acting bronchodilators. Nevertheless, guidelines do not recommend a specific long

Health Technology Assessment (HTA) Database.2009

58. The efficacy and safety of tiotropium in Chinese patients with stable chronic obstructive pulmonary disease: a meta-analysis

The efficacy and safety of tiotropium in Chinese patients with stable chronic obstructive pulmonary disease: a meta-analysis The efficacy and safety of tiotropium in Chinese patients with stable chronic obstructive pulmonary disease: a meta-analysis The efficacy and safety of tiotropium in Chinese patients with stable chronic obstructive pulmonary disease: a meta-analysis Wu Q, Li G, Lei WI, Zhou X CRD summary The review found that among Chinese people with stable (...) chronic obstructive pulmonary disease, tiotropium improved pulmonary function and symptoms, reduced exacerbations and was safe. The authors’ conclusions appear reliable. Authors' objectives To evaluate the safety and efficacy of tiotropium for Chinese people with stable chronic obstructive pulmonary disease (COPD). Searching The Cochrane Library, ClinicalTrials.gov, MEDLINE, EMBASE and major Chinese databases (including 11 listed in the review) were searched for studies published between 2002 and July 2008. Search terms were

DARE.2009

59. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis

Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis Rodrigo GJ, Castro (...) -Rodriguez JA, Nannini LJ, Plaza Moral V, Schiavi EA CRD summary This review evaluated the safety of inhaled tiotropium bromide (anticholinergic agent) in patients with chronic obstructive pulmonary disease. The authors concluded that tiotropium did not significantly increase the risk of adverse major cardiovascular events compared with placebo or salmeterol. The authors' conclusions reflected the evidence presented, but lack of clarity regarding included trial quality means that their reliability

DARE.2009

60. Tiotropium reduced exacerbations but not rate of FEV1 decline in patients with COPD using other respiratory medications

Tiotropium reduced exacerbations but not rate of FEV1 decline in patients with COPD using other respiratory medications Tiotropium reduced exacerbations but not rate of FEV1 decline in patients with COPD using other respiratory medications | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Tiotropium reduced exacerbations but not rate of FEV1 decline in patients with COPD using other respiratory medications Article Text Therapeutics Tiotropium reduced exacerbations but not rate of FEV 1 decline in patients with COPD using other respiratory medications

Evidence-Based Medicine (Requires free registration)2009